Zura Bio Ltd (ZURA): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$64.81M

Year ended 2025-12-31

2022-12-31 Operating Cash Flow (USD) 2025-12-31

Period ended	Operating Cash Flow	Change YoY	Source filing
2025-12-31	-$64.81M	n/m	2026-03-19, From 2025-01-01
2024-12-31	-$28.08M	n/m	2026-03-19, From 2024-01-01
2023-12-31	-$15.05M	n/m	2025-03-25, From 2023-01-01
2022-12-31	-$1.07M	n/a	2023-03-28, From 2022-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Operating Cash Flow	Change YoY
Zura Bio Ltd (ZURA)	2025-12-31	-$64.81M	n/m
Lineage Cell Therapeutics, Inc. (LCTX)	2025-12-31	-$18.92M	n/m
Humacyte, Inc. (HUMA)	2025-12-31	-$105.04M	n/m
Kalaris Therapeutics, Inc. (KLRS)	2025-12-31	-$38.37M	n/m
Acumen Pharmaceuticals, Inc. (ABOS)	2025-12-31	-$115.54M	n/m
Anavex Life Sciences Corp. (AVXL)	2025-09-30	-$39.04M	n/m
Candel Therapeutics, Inc. (CADL)	2025-12-31	-$38.31M	n/m
Pelthos Therapeutics Inc. (PTHS)	2025-12-31	-$22.59M	n/m
Artiva Biotherapeutics, Inc. (ARTV)	2025-12-31	-$76.75M	n/m

Compare ZURA, LCTX, HUMA, KLRS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗